Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Most patients with diffuse large B-cell lymphoma (DLBCL) experience excellent outcomes with first-line immunochemotherapy-based regimens that usually include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and frequently consolidation radiation therapy (RT) to sites at higher risk of local relapse.1-7 Despite these optimal efforts, however, approximately 30% to 40% of patients may experience relapse or primary refractory disease.8 For fit patients, the standard treatment approach in this scenario is usually high-dose chemotherapy and autologous stem cell rescue/transplantation.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oncology Scan Source Type: research